This project aims first to determine the prevalence of sarcopenia in a population of obese people of extended age group (18-70 years). In a second step, the factors determining and / or predisposing to sarcopenic obesity will be identified as well as plasmatic and urinary biomarkers specific to this phenotype.
Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients. Biological collection to identify plasma, serum, genetic, urinary and faecal biomarkers associated with sarcopenic obesity
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
800
Blood, urinary and faecal samples
CHU Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGSarcopenia
The primary endpoint is sarcopenia (present / absent), defined using the muscle mass index (SMI) corresponding to = SM / Height², where the total muscle mass (SM) is calculated from validated equations. by Janssen et al in a population of men and women with a large age range (18-86 years) and adiposity (BMI: 16-48 kg / m integrating bio-impedancemetry data ( BIA).
Time frame: at day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.